The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Seroprevalence of anti-SARS-CoV-2 among blood donors in Rio de Janeiro, Brazil
Open accessAbstract
OBJECTIVE: To estimate the seroprevalence of antibodies to SARS-CoV-2 among blood donors in the state of Rio de Janeiro, Brazil. METHODS: Data were collected on 2,857 blood donors from April 14 to 27, 2020. This study reports crude prevalence of antibodies to SARS-CoV-2, population weighted prevalence for the state, and prevalence adjusted for test sensitivity and specificity. Logistic regression models were used to establish the correlates of SARS-CoV-2 prevalence. For the analysis, we considered collection period and site, sociodemographic characteristics, and place of residence. RESULTS: The proportion of positive tests for SARS-Cov-2, without any adjustment, was 4.0% (95%CI 3.3–4.7%), and the weighted prevalence was 3.8% (95%CI 3.1–4.5%). We found lower estimates after adjusting for test sensitivity and specificity: 3.6% (95%CI 2.7–4.4%) for the non-weighted prevalence, and 3.3% (95%CI 2.6–4.1%) for the weighted prevalence. Collection period was the variable most significantly associated with crude prevalence: the later the period, the higher the prevalence. Regarding sociodemographic characteristics, the younger the blood donor, the higher the prevalence, and the lower the education level, the higher the odds of testing positive for SARS-Cov-2 antibody. We found similar results for weighted prevalence. CONCLUSIONS: Our findings comply with some basic premises: the increasing trend over time, as the epidemic curve in the state is still on the rise; and the higher prevalence among both the youngest, for moving around more than older age groups, and the less educated, for encountering more difficulties in following social distancing recommendations. Despite the study limitations, we may infer that Rio de Janeiro is far from reaching the required levels of herd immunity against SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several countries have monitored seroprevalence in blood transfusion donors or expectant mothers attending antenatal clinics.
“Several countries have monitored seroprevalence in blood transfusion donors (12, 13) or expectant mothers attending antenatal clinics (14).”
From Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors (2021) · cites this paper as [13]
Our results are also comparable with those of other surveys of blood donors in Brazil, Italy, and many parts of England.
“Our results are also comparable with those of other surveys of blood donors in Brazil (13), Italy (12), and many parts of England (19).”
From Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Detection of SARS-CoV-2 in Different Types of Clinical Specimens
Wang, W., Xu, Y., Gao, R., Lu, R., Han, K., Wu, G., & Tan, W. (2020) · JAMA · doi:10.1001/jama.2020.3786 · Cited by 5,116
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Mizumoto, K., Kagaya, K., Zarebski, A. E., & Chowell, G. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.10.2000180 · Cited by 2,317
Jin, Y., Cai, L., Cheng, Z., Cheng, H., Deng, T., Fan, Y., Fang, C., Huang, D., Huang, L., Huang, Q., et al. (2020) · Military Medical Research · doi:10.1186/s40779-020-0233-6 · Cited by 2,306
Li, Z., Yi, Y., Luo, X., Xiong, N., Liu, Y., Li, S., Sun, R., Wang, Y., Hu, B., Chen, W., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25727 · Cited by 1,823
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847
COVID-19 antibody seroprevalence in santa clara county, california
Bendavid, E., Mulaney, B., Sood, N., Shah, S., Bromley-Dulfano, R., Lai, C., Weissberg, Z., Saavedra-Walker, R., Tedrow, J., Bogan, A., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab010 · Cited by 669
COVID-19 Antibody Seroprevalence in Santa Clara County, CaliforniaPreprint
Bendavid, E., Mulaney, B., Sood, N., et al. (2020) · medRxiv · doi:10.1101/2020.04.14.20062463 · Cited by 559
Clinical Characteristics of Covid-19 in China
Chen, A. T. C., Coura-Filho, G. B., & Rehder, M. H. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2005203 · Cited by 478
What policy makers need to know about COVID-19 protective immunity
Altmann, D. M., Douek, D. C., & Boyton, R. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30985-5 · Cited by 223
Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors
Erikstrup, C., Hother, C., Pedersen, O. B., Mølbak, K., Skov, R. L., Holm, D. K., Sækmose, S. G., Nilsson, A. C., Brooks, P. T., Boldsen, J. K., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa849 · Cited by 148
Barreto, M. L., Barros, A. J. D., Carvalho, M. S., Codeço, C. T., Hallal, P. C., Medronho, R. D. A., Struchiner, C. J., Victora, C. G., & Werneck, G. L. (2020) · Revista Brasileira de Epidemiologia · doi:10.1590/1980-549720200032 · Cited by 146
Self-citationCOVID-19 no estado do Ceará, Brasil: comportamentos e crenças na chegada da pandemia
Lima, D. L. F., Dias, A. A., Rabelo, R. S., da Cruz, I. D., Costa, S. C., Nigri, F. M. N., & Neri, J. R. (2020) · Ciência & Saúde Coletiva · doi:10.1590/1413-81232020255.07192020 · Cited by 130
Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donorsPreprint
Erikstrup, C., Hother, C., Pedersen, O. B., et al. (2020) · medRxiv · doi:10.1101/2020.04.24.20075291 · Cited by 70
Herd immunity is not a realistic exit strategy during a COVID-19 outbreakPreprint
Slot, E., Hogema, B. M., Reusken, C. B. E. M., Reimerink, J. H. J., Molier, M., Karregat, J. H. M., IJlst, J., Novotny, V. M. J., van Lier, R. A. W., & Zaaijer, H. L. (2020) · Research Square · doi:10.21203/rs.3.rs-25862/v1 · Cited by 55
The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France
Dimeglio, C., Loubes, J., Deporte, B., Dubois, M., Latour, J., Mansuy, J., & Izopet, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.031 · Cited by 23
Correção da prevalência autorreferida em estudos epidemiológicos com grandes amostras
Moreira, J. P. D. L., de Almeida, R. M. V. R., Rocha, N. C. D. S., & Luiz, R. R. (2016) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00050816 · Cited by 9
Flagged first, then by citations
Cited by
Sorted by citations
Infection fatality rate of COVID-19 inferred from seroprevalence data
Ioannidis, J. P. A. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.265892 · Cited by 684
On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community
Goldstein, E., Lipsitch, M., & Çevik, M. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa691 · Cited by 367
Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
Uyoga, S., Adetifa, I. M. O., Karanja, H. K., Nyagwange, J., Tuju, J., Wanjiku, P., Aman, R., Mwangangi, M., Amoth, P., Kasera, K., et al. (2021) · Science · doi:10.1126/science.abe1916 · Cited by 328
Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review
Lai, C.-C., Wang, J.-H., & Hsueh, P. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.011 · Cited by 193
Community Transmission of SARS-CoV-2 by Surfaces: Risks and Risk Reduction Strategies
Pitol, A. K., & Julian, T. R. (2021) · Environmental Science & Technology Letters · doi:10.1021/acs.estlett.0c00966 · Cited by 156
Mudanças nas condições socioeconômicas e de saúde dos brasileiros durante a pandemia de COVID-19
de Almeida, W. D. S., Szwarcwald, C. L., Malta, D. C., Barros, M. B. D. A., Júnior, P. R. B. D. S., Azevedo, L. O., Romero, D. E., Lima, M. G., Damacena, G. N., Machado, Í. E., et al. (2020) · Revista Brasileira de Epidemiologia · doi:10.1590/1980-549720200105 · Cited by 134
Self-citationThe incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: A systematic review
Al‐Sadeq, D. W., & Nasrallah, G. K. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.06.098 · Cited by 102
Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors
Vena, A., Berruti, M., Adessi, A., Blumetti, P., Brignole, M., Colognato, R., Gaggioli, G., Giacobbe, D. R., Bracci‐Laudiero, L., Magnasco, L., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092780 · Cited by 67
COVID‐19 in Latin America and the Caribbean: Two years of the pandemic
Schwalb, A., Armyra, E., Méndez‐Aranda, M., & Ugarte‐Gil, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13499 · Cited by 71
Epidemiology of COVID-19 in Mexico: Symptomatic profiles and presymptomatic people
Fernández‐Rojas, M. A., Esparza, M. A. L.-R., Campos‐Romero, A., Calva-Espinosa, D. Y., Moreno-Camacho, J. L., Langle-Martínez, A. P., García-Gil, A., Solís-González, C. J., Canizalez‐Román, A., León-Sicairos, N. M., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.12.086 · Cited by 53
Emmenegger, M., Cecco, E. D., Lamparter, D., Jacquat, R. P. B., Riou, J., Menges, D., Ballouz, T., Ebner, D. V., Schneider, M. M., Morales, I. C., et al. (2023) · iScience · doi:10.1101/2020.05.31.20118554 · Cited by 34
Schoenhals, M. J., Rabenindrina, N., Rakotondramanga, J. M., Dussart, P., Randremanana, R. V., Héraud, J., Andriamandimby, S. F., Sahondranirina, P. H., Vololoniaina, M. C., Randriatsarafara, F. M., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103419 · Cited by 34
Zaidi, S. K., Rizwan, F., Riaz, Q., Siddiqui, A., Khawaja, S., Imam, M., Naz, A., Waheed, S., & Shamsi, T. S. (2020) · Journal of Public Health · doi:10.1093/pubmed/fdaa170 · Cited by 34
The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia
Mahallawi, W. H., & Al-Zalabani, A. H. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2020.12.009 · Cited by 35
Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel
Reicher, S., Ratzon, R., Ben-Sahar, S., Alon, S. H., Mossinson, D., Shenhar, Y., Friger, M. D., Lustig, Y., Alroy‐Preis, S., Anis, E., et al. (2021) · European Journal of Epidemiology · doi:10.1007/s10654-021-00749-1 · Cited by 31
Banjar, A., Al‐Tawfiq, J. A., Alruwaily, A., Alserehi, H., Alqunaibet, A., Alaswad, R., Almutlaq, H., Almudaiheem, A., Khojah, A. T., Alsaif, F. K., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.028 · Cited by 32
Herzberg, J., Vollmer, T., Fischer, B., Becher, H., Becker, A., Sahly, H., Honarpisheh, H., Guraya, S. Y., Strate, T. G., & Knabbe, C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.026 · Cited by 29
Gomaa, M. R., Refay, A. S. E., Shehata, M., Kandeil, A., Kamel, M. N., Marouf, M. A., GabAllah, M., Taweel, A. E., Kayed, A. E., Kutkat, O., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009413 · Cited by 29
Bellizzi, S., Alsawalha, L., Ali, S. S., Sharkas, G. F., Muthu, N., Ghazo, M., Aly, E., Rashidian, A., Ariqi, L. A., Hayajneh, W. A., et al. (2021) · One Health · doi:10.1016/j.onehlt.2021.100292 · Cited by 28
Unar‐Munguía, M., Santos‐Guzmán, A., Mota-Castillo, P. J., Ceballos-Rasgado, M., Tolentino‐Mayo, L., Sachse, M., Cobo-Armijo, F., Barquera, S., & Bonvecchio, A. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-009904 · Cited by 27
Coelho, L. E., Luz, P. M., Castanheira, D., Jalil, E. M., Perazzo, H., Torres, T. S., Cardoso, S. W., Peixoto, E. M., Nazer, S., Massad, E., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100338 · Cited by 29
Self-citationSughayer, M. A., Mansour, A. H., Nuirat, A. A., Souan, L., Ghanem, M. A., Siag, M., & Alhassoon, S. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.059 · Cited by 24
Lewin, A., Therrien, R., Serres, G. D., Grégoire, Y., Perreault, J., Drouin, M., Fournier, M., Tremblay, T., Beaudoin, J., Beaudoin-Bussières, G., et al. (2021) · Canadian Journal of Public Health · doi:10.17269/s41997-021-00531-6 · Cited by 23
SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis
Azami, M., Moradi, Y., Moradkhani, A., & Aghaei, A. (2022) · European journal of medical research · doi:10.1186/s40001-022-00710-2 · Cited by 23
The unexpected dynamics of COVID-19 in Manaus, Brazil: Was herd immunity achieved?Preprint
He, D., Artzy‐Randrup, Y. A., Musa, S. S., Gräf, T., Naveca, F. G., & Stone, L. (2021) · medRxiv · doi:10.1101/2021.02.18.21251809 · Cited by 24
Correia, R. F., da Costa, A. C. C., Moore, D. C. B. C., Gomes, S. C., de Oliveira, M. P. C., Zuma, M. C. C., Galvani, R. G. A., Savino, W., Bonomo, A. C., de Vasconcelos, Z. F. M., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100170 · Cited by 22
Seroprevalence of Anti-SARS-CoV-2 Antibodies in Benadir Region, Somalia
Adam, M. H., Mohamoud, J. H., Mohamood, A. S., Mohamed, A. A., Garba, B., & Dirie, N. I. (2022) · Vaccines · doi:10.3390/vaccines10020220 · Cited by 21
Sociodemographic characteristics and risk factors related to SARS-CoV-2 infection in Luanda, Angola
Sebastião, C. S., Neto, Z., Martínez, P. A., Jandondo, D., Antonio, J., Galangue, M., de Carvalho, M., David, K., Miranda, J., Afonso, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249249 · Cited by 20
IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi
Hasan, M. N., Moiz, B., Qaiser, S., Masood, K. I., Ghous, Z., Hussain, A., Ali, N. B., Simas, J. P., Veldhoen, M., Alves, P. M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271259 · Cited by 21
Tadese, E. B., Endris, A. A., Solomon, H., Alayu, M., Kebede, A., Eshetu, K., Teka, G., Eskinder, B., Ahmed, J., Abayneh, S., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.08.028 · Cited by 16
Cavataio, J. P., & Schnell, S. D. (2021) · Mathematical Biosciences · doi:10.1016/j.mbs.2021.108545 · Cited by 16
Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors
Weidner, L., Nunhofer, V., Jungbauer, C., Hoeggerl, A. D., Grüner, L., Grabmer, C., Zimmermann, G., Rohde, E., & Laner‐Plamberger, S. (2021) · Infection · doi:10.1007/s15010-021-01639-0 · Cited by 16
Seroprevalence of SARS-CoV-2 antibodies in 2115 blood donors from Romania
Olariu, T. R., Lighezan, R., Ursoniu, S., Craciun, A. C., Paduraru, A. A., & Lupu, M. A. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.12.027 · Cited by 15
Letizia, A. G., Ge, Y., Goforth, C. W., Weir, D. L., Lizewski, R. A., Lizewski, S. E., Schanoski, A. S., Vangeti, S., Marjanović, N., Sealfon, S. C., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2704.204732 · Cited by 15
Raqib, R., Sarker, P., Akhtar, E., Huda, T. M. N., Haq, M. A., Roy, A. K., Hosen, M. B., Haque, F., Chowdhury, M. R., Reidpath, D. D., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268093 · Cited by 15
Feehan, A. K., Fort, D. G., Velasco, C., Burton, J. H., Garcia‐Diaz, J., Price‐Haywood, E. G., Sapp, E., Pevey, D., & Seoane, L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.12.029 · Cited by 12
Sebastião, C. S., Galangue, M., Gaston, C., Van‐Dunen, R., Quivinja, J., Lunbungululo, E., Alfredo, D., Sozinho, A., Teixeira, A., Manico, E., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06814-0 · Cited by 12
Werneck, G. L., Pôrto, L. C., Sena, A. C., Ferreira, O. D. C., Cavalcanti, A. C., Santos, Â., Secco, D., Silva, M., Mariani, D., Chieppe, A., et al. (2021) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0779-2020 · Cited by 11
Self-citationdo Vale, N. M. R., Latini, F. R. M., Arnoni, C. P., Parreira, R. M., Girão, M. J. B. C., Cortez, A. J. P., & Bonetti, T. C. (2022) · Clinics · doi:10.1016/j.clinsp.2022.100016 · Cited by 10
Saeed, S., Uzicanin, S., Lewin, A., Lieshout‐Krikke, R. W., Faddy, H. M., Erikstrup, C., Osiowy, C., Seed, C. R., Steele, W. R., Davison, K. L., et al. (2021) · Vox Sanguinis · doi:10.1111/vox.13221 · Cited by 9
Menezes, A., Razafimahatratra, S. L., Wariri, O., Graham, A. L., & Metcalf, C. J. E. (2025) · Trends in Microbiology · doi:10.1016/j.tim.2024.12.006 · Cited by 10
Díaz-Salazar, C., Sánchez‐García, A., Rodríguez‐Gutiérrez, R., Camacho-Ortíz, A., Saldívar‐Rodríguez, D., & González‐González, J. G. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06550-5 · Cited by 8
Metzger, C., Leroy, T., Bochnakian, A., Jeulin, H., Gégout‐Petit, A., Legrand, K., Schvoerer, É., & Guillemin, F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0269104 · Cited by 8
Jain, R., Mallya, M. V., Amoncar, S., Palyekar, S., Adsul, H. P., Kumar, R., & Chawla, S. (2021) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2021.07.004 · Cited by 8
Seroprevalence of SARS-CoV-2 in Brazil: A systematic review and meta-analysis
Figueiredo, G. M., Tengan, F. M., Campos, S. R. D. S. L. D. C., & Luna, E. J. D. A. (2023) · Clinics · doi:10.1016/j.clinsp.2023.100233 · Cited by 7
COVID-19, social determinants of transmission in the home. A population-based study
López, J. S., Gómez, J., Ballesta-Ruíz, M., García-Pina, R., Sánchez-Rodríguez, I., Escobar, B. A. B., Salmerón, D., Rodríguez, B. S., & Chirlaque, M. (2024) · European Journal of Public Health · doi:10.1093/eurpub/ckae016 · Cited by 7
Silva, A. V. F. G., Menezes, D., Moreira, F. R. R., Torres, O. A., Fonseca, P. L. C., Moreira, R. G., Alves, H. J., Alves, V. R., Amaral, T. M. D. R., Coelho, A. N., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.799713 · Cited by 7
Prevalence of COVID-19 among blood donors
Elnasser, Z., Obeidat, H. M., Amarin, Z. O., Alrabadi, N., Jaradat, A., Alomarat, D., BaniSalem, M., & Almomani, R. (2021) · Medicine · doi:10.1097/md.0000000000027537 · Cited by 5
Kermani, F. R., Arabkhazaeli, A., Eshghi, P., Maghsudlu, M., Amini‐Kafiabad, S., Teimourpour, A., & Pourkarim, M. R. (2022) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2022.09.003 · Cited by 5
Vermeulen, M., Mhlanga, L., Sykes, W., Cable, R., Coleman, C., Pietersen, N., Swanevelder, R., Glatt, T. N., Bingham, J., van den Berg, K., et al. (2023) · Vox Sanguinis · doi:10.1111/vox.13571 · Cited by 5
Sero-pravelence of SARS CoV-2 IgM and IgG Antibodies Amongst Blood Donors in NigeriaPreprint
Ifeorah, I. M., Nna, E. O., Okeke, U., Ivo, E. A., Ayemoba, O., Yunusa, T., Ochagu, O. R., Ugwu, N. I., Okafor, H. U., Nnamani, A. O., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-151037/v1 · Cited by 5
Hasan, M. S., Moiz, B., Qiaser, S., Ghous, Z., Hussain, A., Masood, K. I., Ali1, N., Simas, J. P., Veldhoen, M., Alves, P. M., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-941908/v1 · Cited by 5
Gaviria, A., Tamayo‐Trujillo, R., Paz‐Cruz, E., Cadena-Ullauri, S., Guevara‐Ramírez, P., Ruiz‐Pozo, V. A., Cevallos, F., Aguirre‐Tello, V., Risueño, K., Yánez, M. P., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1373450 · Cited by 6
Ukwishaka, J., Mela, C. F., Aseneh, J. B., Ettaj, M., Ilboudo, D., Danwang, C., Samadoulougou, S., & Kirakoya‐Samadoulougou, F. (2024) · BMC Public Health · doi:10.1186/s12889-024-20364-5 · Cited by 5
Positive anti-SARS-CoV-2 rapid serological test results among asymptomatic blood donors
Arabkhazaeli, A., Maghsudlu, M., Mohammadi, S., & Eshghi, P. (2021) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2021.08.008 · Cited by 4
Caramelli, B., Escalante-Rojas, M. C., Chauhan, H. K. C., Siciliano, R. F., Bittencourt, M. S., & Micelli, A. C. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05001 · Cited by 3
Das, S., Bera, S., & Biswas, R. N. (2022) · Asian Journal of Transfusion Science · doi:10.4103/ajts.ajts_123_20 · Cited by 3
Asante, I. A., Lwanga, C. N., Takyi, C., Sekyi-Yorke, A. N., Quarcoo, J. A., Odikro, M. A., Kploanyi, E. E., Donkor, I. O., Addo-Lartey, A. A., Duah, N. A., et al. (2024) · Cureus · doi:10.7759/cureus.68220 · Cited by 3
Alzabeedi, K. H., Makhlof, R. T. M., Bakri, R. A., Ewis, A. A., Alhamdi, H. W. S., Habeebullah, T. M., Khogeer, A., Mulla, E. A. A., Roshan, S. A. M., Qabbani, F., et al. (2022) · Vaccines · doi:10.3390/vaccines10081279 · Cited by 3
Seroprevalence of SARS-CoV-2 among Blood Donors in the Republic of Congo
Mokono, S. O., Nanitelamio, E. P. C. L., Mbani, C. J., Tabapika, A., Taty, T., Ontsira, N. E. N., & Moukassa, D. (2022) · Open Journal of Blood Diseases · doi:10.4236/ojbd.2022.124013 · Cited by 3
Kale, P. R., Patel, N., Gupta, E., & Bajpai, M. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103293 · Cited by 3
Seroprevalence of COVID-19 in Blood Donors: A Systematic Review and Meta-Analysis
Nourmohammadi, H., Dehkordi, A. H., Adibi, A., Hashemipour, S. M. A., Abdan, M., Fakhri, M., Abdan, Z., & Sarokhani, D. (2022) · Advances in Virology · doi:10.1155/2022/9342680 · Cited by 3
Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh
Sakalle, S., Saroshe, S., Shukla, H., Mutha, A., Vaze, A., Arora, A., Athotra, A., Ramaswamy, S., Jain, A., Dhuria, M., et al. (2021) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2015_20 · Cited by 3
Refay, A. S. E., Mahmoud, S. H., Marouf, M. A., Gomaa, M. R., Taweel, A. E., Shama, N. M. A., GabAllah, M., Dayem, S. M. A. E., Kandeil, A., Mostafa, A., et al. (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12889 · Cited by 3
Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors
Niederhauser, C., Widmer, N., Tinguely, C., Suter‐Riniker, F., Fontana, S., Buser, A. S., Waldvogel, S., Thierbach, J., Züger, M., & Gowland, P. (2025) · Viruses · doi:10.3390/v17101292 · Cited by 2
Rafael, R. D. M. R., Correia, L. M., de Mello, A. S., Prata, J. A., Gallasch, C. H., Júnior, E. F. P., Silva, F. V. C. E., Penna, L. H. G., Caravaca‐Morera, J. A., Breda, K. L., et al. (2021) · Escola Anna Nery · doi:10.1590/2177-9465-ean-2020-0528 · Cited by 2
Rajabinejad, M., & Asgarian‐Omran, H. (2021) · medRxiv · doi:10.1101/2021.05.23.21257692 · Cited by 2
Gomes, K. M., Leite, S. P., Moutinho, M. H. V., de Souza, T. A., Batista, R. D. C., de Oliveira, L. C. M., Redner, P., Ramos, J. P., da Rocha, F. M. G., de Oliveira, G. P., et al. (2021) · medRxiv · doi:10.1101/2021.11.17.21266274 · Cited by 2
Seroprevalence of COVID-19 among voluntary blood donors
Pothipillai, A., Hamsavardhini, S., Duraisamy, D., Thiyagarajan, L., Kaliyaperumal, C., & Rao, J. G. V. M. (2023) · Asian Journal of Transfusion Science · doi:10.4103/ajts.ajts_91_23 · Cited by 1
Perfil epidemiológico da pandemia de COVID-19 e características do agente etiológico: Revisão
Nogueira, A. B., Silva, C. V. D. S., da Silva, L. M., de Freitas, M. R., & Knackfuss, F. B. (2021) · PubVet · doi:10.31533/pubvet.v15n06a845.1-11 · Cited by 1
Panorama da infecção pelo SARS-COV-2 no Centro de Progressão Penitenciária do Butantan
Andrade, S. G. D. A., Andrade, F., Silva, A., Cardoso, M. R. A., Ferraz, G. R., de Barros, E. N. C., Braga, P. E., Cristófalo, M. M., Vieira, J., Lopes, C. D. S., et al. (2023) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2023057004717 · Cited by 1
Dhaouadi, S., Letaief, H., Hechaichi, A., Safer, M., Moussa, R., Bouhali, R., Letaief, F., Abdelkader, L., Salah, H. B., Mili, N. E., et al. (2023) · Epidemiologia · doi:10.3390/epidemiologia4020020 · Cited by 1
Tasew, G., Abdella, S., Bejiga, B., Ayalew, J., Tessema, M., Bati, F., Ali, A., Negash, L., Tadese, E. B., Tollera, G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313791 · Cited by 1
COVID-19 Immunoglobulin G Antibodies in Healthy Blood Donors Paving Way to Herd Immunity
Sareen, R., Gupta, G., Agarwal, P. K., & Saini, S. (2021) · Global Journal of Transfusion Medicine · doi:10.4103/gjtm.gjtm_9_21 · Cited by 1
Seroprevalence of Anti-SARS-COV-2 Antibodies in Benadir Region, SomaliaPreprint
Dirie, N. I., Adam, M. H., Mohamoud, J. H., Mohamood, A. S., & Mohamed, A. A. (2021) · Research Square · doi:10.21203/rs.3.rs-961632/v1
Chunchu, S. R., Bala, S., Rajiv Kumar, B., & Ravula, U. (2022) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v13i2.40867
Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal
Costa, J. P., Meireles, P., Rodrigues, P., & Barros, H. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2035429 · Cited by 2
Study of seroprevalence of antibodies to SARS-COV-2 among the healthy blood donors of Jammu region
Dutt, N., Sharma, S., & Sidhu, M. (2022) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20220298
Perfil epidemiológico da pandemia de COVID-19 e características do agente etiológico: Revisão
de Freitas, M. R., Barreto, A., Vasconcelos, C., de Melo, L. N., & Knackfuss, F. B. (2021) · PubVet · doi:10.31533/pubvet.v15n03a845.1-11
Seroprevalence of Sars-Cov-2 antibodies among eligible blood donors of Peshawar, Pakistan.
Khan, M. N., Khan, H., Shahzad, M. A., bin Ibrahim, M., Arif, M., Kibria, Z., Waheed, U., Saba, N., Shah, I., Sumera, et al. (2022) · PubMed Central
Prevalence of bacterial co infections among Covid 19 patients in wasit province
Hussein, M. N., AL-Saadi, Z. N., Al-Azzawi, J. A. T., & Hussein, D. N. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns7.13709
Abdelrazik, A. M., Sauza, R. B., & Abdelaziz, H. (2023) · Egyptian Journal of Medical Research · doi:10.21608/ejmr.2023.166111.1274
Kermani, F. R., Eshghi, P., Maghsudlu, M., Amini‐Kafiabad, S., Teimourpour, A., & Pourkarim, M. R. (2023) · Jundishapur Journal of Microbiology · doi:10.5812/jjm-135768
COVID-19 in a Portuguese whole blood donor population
Fonseca, L., Pereira, F. M., Moura, L. M., Brito, A., Lobo, F., Amaral, A. P., & Costa, M. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20570
Alghamdi, A., Alandijany, T. A., Faizo, A. A., El-Kafrawy, S. A., Hassan, A. M., Tolah, A. M., Qashqari, F. S., Sohrab, S. S., Hindawi, S., Badawi, M. A., et al. (2025) · Journal of Visualized Experiments · doi:10.3791/67886
SARS-CoV-2 sero-surveillance after the first and second waves of the epidemic in PanamaPreprint
Lezcano-Coba, C., Galué, J., Whittaker, C., Mills, C. L., de Antonio, R., Sánz-Llorens, X., Rivera, L. F., Rodríguez, X., Franco, D., Rebollón, A., et al. (2025) · medRxiv · doi:10.1101/2025.07.20.25331847
Muchanga, V., Huo, L., Kampa, K. T., Chilundo, B., Munguambe, K., & Moon, T. D. (2025) · Frontiers in Reproductive Health · doi:10.3389/frph.2025.1667930
Rakotondramanga, J. M. (2023) · theses.fr (ABES) · doi:10.70675/aae0cc9az3b0fz4ccdzb05az583a89448b7d
Onyeaghala, C., Unigwe, U. S., Chika-Igwenyi, N. M., & Iroezindu, M. O. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-14139-z
Metadata
- Authors
- Amorim Filho, L., Szwarcwald, C. L., Mateos, S. D. O. G., Ponce de Leon, A. C. M., Medronho, R. D. A., Veloso, V. G., Lopes, J. I. F., Porto, L. C. D. M. S., Chieppe, A., & Werneck, G. L.
- Affiliations
- Instituto de Comunicação e Informação Científica e Tecnológica em Saúde (BR)
- Hemorio (BR)
- Universidade Federal do Rio de Janeiro (BR)
- Universidade de São Paulo (BR)
- Governo do Estado do Rio de Janeiro (BR)
- ORCID
- Venue
- Revista de Saúde Pública
- Published
- 2020-07-06
- Volume
- 54
- Pages
- 69
- ISSN
- 0034-8910 (ISSN-L)
- 1518-8787
- PMC
- PMC7334006
- OpenAlex
- W3039651317
- Cited by
- 90
- References
- 20
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 4 · 2023: 11 · 2022: 19 · 2021: 38 · 2020: 11
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Revista de Saúde Pública (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Hematology › Blood donation and transfusion practices
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, SARS-CoV-2 antibodies, blood donors, Rio de Janeiro, herd immunity, sensitivity and specificity, sociodemographic factors, age and education, social distancing
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Antibodies, Viral, Blood Donors, Brazil, Cross-Sectional Studies, Female, Humans, Immunoglobulin G, Immunoglobulin M, Male, Middle Aged, Pneumonia, Viral, Regression Analysis, Sensitivity and Specificity, Prevalence, Seroepidemiologic Studies, Coronavirus Infections, Young Adult, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
